Dodecanoate

Dodecanoate

SCHEMBL138674

CCCCCCCCCCCC(=O)[O-].O=S(=O)([O-])[O-].[Na+].[Na+].[Na+]

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Dodecanoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.67
FABP3 P05413 7/20 0.62
CES2 O00748 4/20 0.56
CES1 P23141 4/20 0.56
NFKB1 P19838 1/20 0.55
GPR84 Q9NQS5 1/20 0.53
FFAR3 O14843 1/20 0.52
HDAC3 O15379 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC8 Q9BY41 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Myristic Acid SCHEMBL4230929 1.00 CA1 (0.67) CA1FABP3CES2CES1NFKB1
Palmitic Acid SCHEMBL8511539 1.00 CA1 (0.67) CA1FABP3CES2CES1NFKB1
Stearic Acid SCHEMBL7042513 0.96 FABP3 (0.62) CA1FABP3CES2CES1NFKB1
Stearic Acid SCHEMBL31357301 0.96 FABP3 (0.62) CA1FABP3CES2CES1NFKB1
Stearic Acid SCHEMBL31210069 0.96 FABP3 (0.62) CA1FABP3CES2CES1NFKB1
Stearic Acid SCHEMBL10488816 0.96 FABP3 (0.62) CA1FABP3CES2CES1NFKB1
Dodecanoate SCHEMBL8140299 0.96 FABP3 (0.62) CA1FABP3CES2CES1NFKB1
Octanoic Acid SCHEMBL3283210 0.96 FABP3 (0.62) CA1FABP3CES2CES1NFKB1
Stearic Acid SCHEMBL1002937 0.96 FABP3 (0.62) CA1FABP3CES2CES1NFKB1
Stearic Acid SCHEMBL18197505 0.96 FABP3 (0.62) CA1FABP3CES2CES1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12487224-B2 Soil analysis compositions and methods PRECISION PLANTING LLC (US) 2025-12-02 US claimed
US-12352740-B2 Soil analysis compositions and methods PRECISION PLANTING LLC (US) 2025-07-08 US claimed
EP-4182660-B1 SOIL ANALYSIS COMPOSITIONS AND METHODS PREC PLANTING LLC (US) 2025-07-02 EP claimed
EP-4182669-B1 SOIL ANALYSIS METHODS PREC PLANTING LLC (US) 2025-07-02 EP claimed
EP-4182659-B1 SOIL ANALYSIS METHOD PREC PLANTING LLC (US) 2025-07-02 EP claimed
WO-2025051022-A1 TECHNETIUM [99TC] METHYLENE DIPHOSPHONATE ORAL FORMULATION, PREPARATION METHOD THEREFOR, AND USE THEREOF 成都云克药业有限责任公司 2025-03-13 WO claimed
CN-119111517-A Air response type long-acting stable chlorine dioxide sustained-release tablet 广西艾科宁消毒科技有限公司 2024-12-13 CN claimed
US-20240301326-A1 CAGELESS SELF-ADHESIVE LAVATORY CLEANING COMPOSITION Reckitt Benckiser Health Limited (GB) 2024-09-12 US claimed
CN-118393828-A Stripping composition of high heat resistance photoresist and application thereof 上海飞凯材料科技股份有限公司 2024-07-26 CN claimed
EP-4373906-A1 CAGELESS SELF-ADHESIVE LAVATORY CLEANING COMPOSITION Reckitt & Colman (Overseas) Hygiene Home Limited (GB) 2024-05-29 EP claimed
WO-2015100348-A1 KELOID REDUCTION USING TOPICAL ALLANTOIN SCIODERM, INC. (US) 2015-07-02 WO claimed
US-20150133543-A1 TOPICAL GEL COMPOSITION COMPRISING AN INGENOL DERIVATIVE AND A SOLVENT MIXTURE LEO LABORATORIES LIMITED (IE) 2015-05-14 US claimed
EP-2858629-A1 A TOPICAL GEL COMPOSITION COMPRISING AN INGENOL DERIVATIVE AND A SOLVENT MIXTURE Leo Laboratories Limited (IE) 2015-04-15 EP claimed
US-20140288137-A1 COMPOSITIONS AND METHODS OF TREATMENT OF INFLAMMATORY SKIN CONDITIONS USING ALLANTOIN SCIODERM, INC. (US) 2014-09-25 US claimed
US-20140206732-A1 Compositions and Methods of Treatment of Inflammatory Skin Conditions Using Allantoin SCIODERM, INC. (US) 2014-07-24 US claimed
US-20140194482-A1 COMPOSITIONS AND METHODS OF TREATMENT OF INFLAMMATORY SKIN CONDITIONS USING ALLANTOIN WILMINGTON TRUST, NATIONAL ASSOCIATION 2014-07-10 US claimed
US-20140121255-A1 Methods of Treating Psoriasis Using Allantoin SCIODERM, INC. (US) 2014-05-01 US claimed
WO-2013182688-A1 A TOPICAL GEL COMPOSITION COMPRISING AN INGENOL DERIVATIVE AND A SOLVENT MIXTURE LEO LABORATORIES LIMITED (IE) 2013-12-12 WO claimed
WO-2008042557-A2 FORMULATION AND METHOD FOR A SHAMPOO FOR ANIMALS EPIDERMAPET, LLC (US) 2008-04-10 WO claimed
US-20080081036-A1 FORMULATION AND METHOD FOR A SHAMPOO FOR ANIMALS EPIDERMA PET, LLC (US) 2008-04-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288137-A1 COMPOSITIONS AND METHODS OF TREATMENT OF INFLAMMATORY SKIN CONDITIONS USING ALLANTOIN CUTA, ITCH, ARG1 CA1 1533/4885FABP3 1829/4885CES2 1659/4885
US-20140194482-A1 COMPOSITIONS AND METHODS OF TREATMENT OF INFLAMMATORY SKIN CONDITIONS USING ALLANTOIN CUTA, ITCH, ARG1 CA1 1533/4885FABP3 1829/4885CES2 1659/4885
US-20140206732-A1 Compositions and Methods of Treatment of Inflammatory Skin Conditions Using Allantoin CUTA, ITCH, ARG1 CA1 1533/4885FABP3 1829/4885CES2 1659/4885
US-20140121255-A1 Methods of Treating Psoriasis Using Allantoin CUTA, ITCH, PPIA CA1 1224/4885FABP3 1690/4885CES2 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.